Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions

(2015) Danielle M. Lussier et al.   JOURNAL OF IMMUNOTHERAPY

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Programmed Cell Death Ligand 1 Expression in Osteosarcoma

(2014) J. K. Shen et al.   Cancer Immunology Research

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

Deciphering and Reversing Tumor Immune Suppression

(2013) Greg T. Motz et al.   IMMUNITY

PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells

(2013) Erin E. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

B7 family checkpoint regulators in immune regulation and disease

(2013) Sabrina Ceeraz et al.   TRENDS IN IMMUNOLOGY

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice

(2012) François-Xavier Dieudonné et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy

(2012) Yi Li et al.   LEUKEMIA & LYMPHOMA

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion

(2011) Kimberly A. Hofmeyer et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Understanding Micrometastatic Disease and Anoikis Resistance in Ewing Family of Tumors and Osteosarcoma

(2010) S. J. Strauss et al.   ONCOLOGIST

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

(2010) Junko Matsuzaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB

(2009) Jae Yeo Park et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD

Immune surveillance: a balance between protumor and antitumor immunity

(2008) Suzanne Ostrand-Rosenberg   CURRENT OPINION IN GENETICS & DEVELOPMENT